One of the cleanest ways to boost your growth hormone. It tells your pituitary to release more GH without messing with cortisol (your stress hormone) or prolactin, which means fewer side effects than other GH peptides.
What to Expect
Week 1–2
Improved sleep depth and quality (often the first noticeable effect). Mild increase in hunger around injection time. Subtle boost in recovery.
Week 3–6
Better workout recovery and muscle fullness. Beginning of fat loss, especially around midsection. Improved skin quality. Enhanced overall well-being.
Week 8+
Measurable improvements in body composition. Joint and tendon repair. Sustained sleep benefits. Hair and nail growth. Anti-aging skin effects.
Common Side Effects
Scientific Overview
Ipamorelin is a pentapeptide growth hormone secretagogue (GHS) that selectively activates the ghrelin/GHS receptor (GHSR-1a) on pituitary somatotrophs. Unlike GHRP-6 and GHRP-2, Ipamorelin does not significantly stimulate ACTH, cortisol, or prolactin release, providing a cleaner GH-specific signal. In clinical studies, it demonstrated dose-dependent GH release with a potency comparable to GHRP-6 but superior selectivity. Its pentapeptide structure (Aib-His-D-2Nal-D-Phe-Lys-NH2) confers resistance to enzymatic degradation.
Dosing
200-300 mcg subq 2-3 times daily, ideally before bed. Cycle for 8-12 weeks.
Practical Guide
Reconstitution
Mix 5mg vial with 2.5mL BAC water. Each 0.1mL = 200mcg.
Storage
Refrigerate after reconstitution. Use within 30 days.
Injection Sites
Subcutaneous with 29-31g insulin syringe. Can be drawn into the same syringe as CJC-1295 No DAC.
Timing
Best injected 30 minutes before bed on empty stomach. Second dose upon waking (before breakfast) for 2x/day protocols.
Food
Must inject on empty stomach. No food for at least 20-30 minutes after injection. Fats especially blunt GH response.
Benefit Profile
Medical Considerations
Contraindications
- ✕Active cancer
- ✕Pituitary tumors
- ✕Pregnancy/nursing
- ✕Uncontrolled diabetes
Drug Interactions
Recommended Monitoring
- →IGF-1 levels every 3-6 months
- →Fasting glucose at baseline and quarterly
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol.
Published Research
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.
[Ghrelin-related drugs: clinical perspectives].
[Structure-activity relationship of ghrelin].
The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.
The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.
Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics.